InflaRx on large white.jpg
InflaRx Reports Full Year 2023 Results and Announces INF904 Development Plans
March 21, 2024 07:00 ET | InflaRx N.V.
InflaRx will focus development activities and resources initially on selected indications in immuno-dermatology, with registrational-phase vilobelimab and potentially best-in-class oral C5aR inhibitor...
InflaRx on large white.jpg
InflaRx to Announce Development Plans for INF904 and 2023 Financial Results on March 21, 2024
March 19, 2024 07:30 ET | InflaRx N.V.
JENA, Germany, March 19, 2024 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today...
InflaRx on large white.jpg
InflaRx Appoints Jan Medina as Head of Investor Relations
February 22, 2024 07:30 ET | InflaRx N.V.
JENA, Germany, Feb. 22, 2024 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today...
InflaRx on large white.jpg
InflaRx Announces Initiation of its Commitment Program for GOHIBIC®(vilobelimab) to Help Broaden Access for Eligible Patients
January 25, 2024 07:30 ET | InflaRx N.V.
InflaRx to cover costs of GOHIBIC for patients who are treated in line with its Emergency Use Authorization (EUA) but do not survive. InflaRx is determined to support broader access to GOHIBIC for...
InflaRx on large white.jpg
InflaRx Announces Positive Topline Results from the Multiple Ascending Dose (MAD) Phase I Study with C5aR Inhibitor INF904
January 04, 2024 07:00 ET | InflaRx N.V.
MAD pharmacokinetic and pharmacodynamic data support best-in-class potential of INF904 over tested dose range of 30 mg once per day (QD) to 90 mg twice per day (BID) for 14 days: Achieved ≥90%...
InflaRx on large white.jpg
InflaRx Announces First Patient Dosed in Phase III Trial with Vilobelimab in Pyoderma Gangrenosum
November 06, 2023 07:30 ET | InflaRx N.V.
Multi-national, randomized, controlled adaptive Phase III study in ulcerative pyoderma gangrenosum (PG) initiated and first patient dosed in the U.S.PG is a rare and debilitating autoimmune skin...
InflaRx on large white.jpg
InflaRx Reports Third Quarter 2023 Financial Results and Provides Business Update
November 01, 2023 07:30 ET | InflaRx N.V.
Single ascending dose (SAD) Phase I data confirm best-in-class potential of orally available C5aR inhibitor INF904; multiple ascending dose (MAD) part ongoingSix clinical sites initiated; first...
InflaRx on large white.jpg
InflaRx Announces Positive Topline Results from the Single Ascending Dose (SAD) Phase I Study with C5aR Inhibitor INF904
September 11, 2023 07:00 ET | InflaRx N.V.
SAD data confirm best-in-class potential for INF904 as orally administered C5aR inhibitor: Safety and tolerability with no signals of concern over entire dose rangePharmacokinetics (PK): favorable...
InflaRx on large white.jpg
InflaRx’s Marketing Authorization Application (MAA) for Vilobelimab for Treatment of Critically Ill COVID-19 Patients under Review by European Medicines Agency (EMA)
August 30, 2023 07:30 ET | InflaRx N.V.
MAA for vilobelimab was submitted in JulyMAA has been validated by EMA and is now under reviewRegulatory submission based on pivotal data from PANAMO Phase III trialCompany announces attendance at...
InflaRx on large white.jpg
InflaRx Reports Second Quarter 2023 Financial Results & Operating Update
August 10, 2023 07:30 ET | InflaRx N.V.
• Quarter highlighted by the Emergency Use Authorization (EUA) and commercial launch of Gohibic (vilobelimab) in the United States • Oral C5aR inhibitor INF904 progressing in...